08:00 , Nov 21, 2005 |  BC Week In Review  |  Company News

Abeille scientific advisory board update

Abeille Pharmaceuticals Inc. , Princeton, N.J.   Business: Drug delivery   Appointed: John Babish, SVP of Ashni Naturaceuticals Inc. ; Douglas Flanagan, professor of pharmaceutics at the University of Iowa; Om Ganda, associate clinical professor...
07:00 , Oct 22, 2001 |  BC Week In Review  |  Company News

Silico Insights Inc. management update

Silico Insights Inc., Woburn, Mass.   Business: Bioinformatics   Hired: Dinesh Patel, a director, as chairman and CEO; he will remain president, chairman and CEO of Ashni Naturaceuticals Inc.  ...
08:00 , Mar 19, 2001 |  BC Week In Review  |  Company News

Ashni, Silico Insights Inc. deal

Ashni and Silico will characterize the anti-inflammatory activity of mixtures of natural compounds and identify regulatory and post-translational pathways of compounds using Ashni's BIOPrinting technology for genomic and proteomic analysis and Silico's informatics expertise. Ashni...
07:00 , Aug 7, 2000 |  BC Week In Review  |  Company News

Silico Insights Inc. board of directors update

Silico Insights Inc. , Woburn, Mass.   Business: Enabling technology   Appointed: Dinesh Patel, president and CEO of Ashni Nutraceuticals Inc. and Salus Therapeutics Inc. ; and Frank Montgomery, general partner at Moss Forest Ventures...
08:00 , Mar 20, 2000 |  BC Week In Review  |  Company News

PharmQuest.com board of directors update

PharmQuest.com, San Jose, Calif.   Business: Enabling technology   Appointed: Boyd Poulsen, former SVP of pharmaceutical development at Syntex Corp., as chairman; Dinesh Patel, chairman, president and CEO of Ashni Naturaceuticals Inc. ; and James...
08:00 , Feb 22, 2000 |  BC Week In Review  |  Company News

Ashni, Elan deal

The companies will develop and market nutritional products created with Ashni’s Genomic BIOprinting compound profiling technology and ELN’s NanoCrystal bioavailability technology. ELN made an equity investment in Ashni and will provide product development funding. Ashni...
08:00 , Feb 15, 2000 |  BC Extra  |  Company News

Two more alliances for Elan

Athersys (Cleveland, Ohio) and ELN formed a joint venture to develop a protein to treat AIDS-related muscle wasting. The venture will combine Athersys' Random Activation of Gene Expression (RAGE) technology with ELN's Medipad drug delivery...
08:00 , Jan 31, 2000 |  BC Week In Review  |  Company News

Ashni, BioNexus Genomics Inc. deal

Ashni acquired BioNexus in a stock transaction under which BioNexus shareholders will own 50 percent of Ashni. Ashni will use BioNexus' BIOprinting process, which uses a combination of genomic and proteomic analysis to develop dietary...